Primary small-bowel non-Hodgkin's lymphoma: a study of clinical features, pathology, management and prognosis.
The records of 34 patients diagnosed with primary small bowel non-Hodgkin's lymphoma during a 10-year period between January 1996 and December 2005, including 27 cases for which complete follow-up records were available, were studied. Abdominal pain (70.6% of patients) was the main presenting symptom, followed by intestinal obstruction (38.2%). The most common primary site was the ileum (58.8%), followed by the jejunum (26.5%) and duodenum (17.6%); one case had tumours at two sites in the small bowel. Twenty-seven patients had small bowel B-cell lymphoma (24 diffuse large B-cell lymphoma; three mucosa-associated lymphoid tissue B-cell lymphoma) and seven patients had small bowel T-cell lymphoma. Cumulative survival in patients with small bowel B-cell lymphoma was higher than that in patients with small bowel T-cell lymphoma. Data on 16 male and eight female patients with diffuse large B-cell lymphoma showed that 62.5% of these patients presented with disease stages I or II and 37.5% with stages III or IV. Cumulative survival in patients at stages IE or IIE was significantly higher than that of patients at stages IIIE or IVE. Four of five patients who died from diffuse large B-cell lymphoma had abnormal levels of lactate dehydrogenase and serum albumin.
Yin
L
L
Department of General Surgery, Ruijin Hospital of Shanghai, Shanghai Jiaotong University, Shanghai, People's Republic of China. yindalu@yahoo.com.cn
Chen
C Q
CQ
Peng
C H
CH
Chen
G M
GM
Zhou
H J
HJ
Han
B S
BS
Li
H W
HW
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000209:etiology* / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D007421:Intestine, Small / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000209:etiology* / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome